Research programme: myocardial infarction therapy - ITL Pharma

Drug Profile

Research programme: myocardial infarction therapy - ITL Pharma

Alternative Names: CardioSafe

Latest Information Update: 28 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ITL Pharma
  • Class Cardiovascular therapies
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Myocardial infarction

Most Recent Events

  • 21 Feb 2017 Research programme: myocardial infarction therapy - ITL Pharma is available for licensing as of 21 Feb 2017.
  • 21 Feb 2017 Early research in Myocardial infarction in USA (unspecified route)
  • 18 Mar 2014 ITL Pharma has patent protection for free radical scavengers in USA (ITL Pharma website)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top